Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. The Study Group of Ubenimex for BMT.
Hiraoka
A
A
Center for Adult Diseases, Osaka, Japan.
Shibata
H
H
Masaoka
T
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D006087:Graft vs Host Reaction / Q000276:immunology*; D006801:Humans; D007223:Infant; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000601:surgery*; D008297:Male; D012008:Recurrence
D000276:Adjuvants, Immunologic; D007930:Leucine; C012211:ubenimex